United Therapeutics (UTHR) vs Viatris (VTRS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Viatris (VTRS) has outperformed United Therapeutics (UTHR) over the past year, gaining 74.9% versus a gain of 19.3%. Over five years, UTHR leads with a +191.3% price change compared with +29.6% for VTRS. United Therapeutics is the larger company by market cap ($22.85 billion vs $20.03 billion), about 1.1 times the size.
On valuation, Viatris trades at a lower forward P/E (6.5x vs 17.0x for United Therapeutics). Viatris pays a dividend yielding 2.75%, while United Therapeutics does not currently pay one. United Therapeutics converts more of its revenue into profit, with a net margin of 41.9% versus -24.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | UTHR | VTRS |
|---|---|---|
| Share price | $532.78 | $17.44 |
| Market cap | $22.85B | $20.03B |
| 1-day change | -2.24% | -0.29% |
| YTD return | +11.85% | +40.08% |
| 1-year return | +19.30% | +74.92% |
| 5-year return | +191.33% | +29.57% |
| P/E ratio (TTM) | 19.08 | — |
| Forward P/E | 17.04 | 6.52 |
| EPS (TTM) | $27.92 | $-0.36 |
| Dividend yield | 0.00% | 2.75% |
| Annual dividend | $0.00 | $0.48 |
| Revenue (latest FY) | $3.18B | $14.30B |
| Revenue growth (YoY) | +10.61% | -2.98% |
| Net income (latest FY) | $1.33B | $-3.51B |
| Gross margin | 87.92% | 35.06% |
| Operating margin | 46.89% | -18.62% |
| Net margin | 41.94% | -24.58% |
| 52-week high | $609.35 | $18.43 |
| 52-week low | $409.07 | $9.69 |
| Distance from 52-week high | -12.57% | -5.37% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +21.93% | +12.96% |
| Average volume | 655.10K | 9.18M |
| Shares outstanding | 42.89M | 1.15B |
| Employees | 1,400 | 30,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VTRS has outperformed UTHR by 55.6 percentage points over the past year.
- Viatris offers a meaningfully higher dividend yield (2.75% vs 0.00%).
- United Therapeutics is more profitable, keeping 41.9 cents of every revenue dollar as net income versus -24.6 cents for Viatris.
- United Therapeutics grew revenue faster in its latest fiscal year (+10.61% vs -2.98%).
About United Therapeutics
UTHR stock →United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,400 employees
About Viatris
VTRS stock →Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets.
Health Care · Biotechnology: Pharmaceutical Preparations · 30,000 employees
UTHR vs VTRS FAQ
Which is bigger, United Therapeutics or Viatris?
United Therapeutics (UTHR) is larger, with a market capitalization of $22.85B compared with $20.03B for Viatris (VTRS).
Which stock has performed better over the past year, UTHR or VTRS?
VTRS returned +74.92% over the past 12 months, compared with +19.30% for UTHR (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, United Therapeutics or Viatris?
Viatris pays a dividend yielding 2.75%, while United Therapeutics does not currently pay a regular dividend.
Are United Therapeutics and Viatris in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.